JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Predictive factors for the response to neoadjuvant treatment in patients with stage II and III breast cancer

  • 0Postgraduate Program in Biosciences and Health.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ecp) +

|

April 2, 2025

|

April 2, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Younger breast cancer patients (≤39) and those with specific subtypes responded better to neoadjuvant treatment. Diabetes and advanced stages (IIIB/IIIC) were linked to poorer outcomes, emphasizing diabetes management in cancer care.

Area Of Science

  • Oncology
  • Clinical Research
  • Breast Cancer Treatment

Background

  • Neoadjuvant treatment is crucial for managing stage II and III breast cancer.
  • Identifying factors predicting treatment response is essential for personalized oncology.
  • Understanding these factors can optimize therapeutic strategies and patient outcomes.

Purpose Of The Study

  • To identify predictive factors for response to neoadjuvant treatment in stage II and III breast cancer patients.
  • To analyze the association between patient demographics, molecular subtypes, comorbidities, and treatment response.
  • To provide insights for improving neoadjuvant chemotherapy efficacy.

Main Methods

  • Cross-sectional study of 440 breast cancer patients (stage II-III) treated between 2007-2022.
  • Response assessment included pathological complete response (pCR), partial response, and no response.
  • Multinomial regression analysis was used to identify predictive factors.

Main Results

  • Younger patients (≤39 years) were more likely to achieve pCR (RR=3.04).
  • Luminal A and B subtypes showed a lower likelihood of pCR (RR=0.09).
  • Diabetes (RR=7.18) and advanced stages (IIIB/IIIC, RR=7.41) significantly increased the risk of no response.

Conclusions

  • Age, molecular subtype, and tumor stage are significant predictors of neoadjuvant treatment response.
  • Diabetes is a critical factor associated with poorer treatment outcomes in breast cancer.
  • Further research into the mechanism of diabetes impacting neoadjuvant treatment response is warranted, alongside proactive diabetes management in cancer patients.